Study study type PathologyT1T0Patientssample sizesROB Results

mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant

versus placebo plus SoC
atezolizumab plus SoC
IMspire-150 (BRAF mutant), 2020
  NCT02908672
RCTmML - L1 - BRAF mutantatezolizumab plus cobimetinib plus vemurafenibplacebo plus cobimetinib plus vemurafenibpatients previously untreated BRAFv600 mutation-positive metastatic or unresectable locally advanced melanoma.256 / 258low
suggested
  • suggested 22 % decrease in progression or deaths (PFS) (PE)